Entera Bio (ENTX) risk factors
Item 1A of every Entera Bio Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors72 risks3 new2 dropped8 reworded
Entera Bio faces severe going concern doubts with cash runway only into mid-third quarter 2026. Net losses worsened to $11.4 million in 2025, with an accumulated deficit of $125.4 million. Clinical development relies heavily on the oral N-Tab platform and partnerships with OPKO.
Filed Mar 27, 2026 - FY2024 10-K risk factors71 risks
Entera Bio faces substantial going concern doubt with an accumulated deficit of $113.9 million as of December 31, 2024. Operations are concentrated on advancing the lead osteoporosis candidate EB613 and the N-Tab platform. The Israel-Hamas War poses a specific threat to meeting contractual collaboration obligations and business relationships.
Filed Mar 28, 2025